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We report a case of ocular ischemic syndrome accompanied by neovascular glaucoma that was successfully 
treated with Bevacizumab. A 70-year-old male patient diagnosed with neovascular glaucoma of the left eye 3-4 
years prior complained of continuous left eye pain and declining visual acuity despite receiving the latest treatment 
methods. At the time of admission the patient had no light perception in the left eye and his intraocular 
pressure was 30 mmHg. Anterior segment and fundus examinations revealed neovascularization of the iris and 
stenosis of the retinal vessel. Hypofluorescence of the choroid and retinal vessels was observed on 
fluorescence fundus angiography. Left internal carotid artery stenosis was observed on a brain MRI. Despite 
being treated with eye solution and oral medication, intraocular pressure was not controlled. After 7 days, we 
performed an intravitreal Bevacizumab 1.25 mg/0.05mL injection. One day after the intravitreal Bevacizumab 
injection, the neovascularization had nearly regressed and intraocular pressure was 30 mmHg. Intravitreal 
Bevacizumab injection produced regression of neovascularization and proved effective for treatment of 
neovascular glaucoma in this case of ocular ischemic syndrome.
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Fig. 1. Slit lamp examination demonstrated 6 clock hours of angle 
neovascularization with synechiae in the left eye.
Ocular ischemic syndrome occurs in about 5% of patients 
diagnosed with severe carotid artery occlusion (>90%), and 
may lead to neovascular glaucoma (NVG) due to the growth 
of blood vessels on the iris surface and anterior chamber 
angle. NVG develops in about 1/3 of cases of ocular ischemic 
syndrome. Vascular endothelial growth factor (VEGF) is the 
most thoroughly studied angiogenic peptide implicated in 
ischemic retinal disease and NVG.
1 VEGF is mitogen specific 
for vascular endothelial cells, and recently, the intravenous 
use of an anti-VEGF antibody, bevacizumab (Avastin) has 
been applied to target vessel formation for treatment of colo-
rectal cancer. Intravenous and intravitreal injection of beva-
cizumab has also been reported to have anatomical and 
functional success for treating choroidal neovascularization 
and macular edema.
2 We report a successful case of intra-
vitreal injection of bevacizumab for the treatment of iris and 
angle neovascularization in a patient with NVG secondary to 
ocular ischemic syndrome.
Case Report
A 70-year-old patient with a 4-year history of neovascular 
glaucoma due to ischemic retinopathy in the left eye and 
vertigo visited our hospital after having received the maximal 
medical therapy for intraocular pressure (IOP) control and 
panretinal photocoagulation (PRP) at another facility. He had 
experienced a total lack of light perception in the left eye for 
3 years and his IOP was 30 mmHg. Slit lamp examination 
demonstrated 6 clock hours of angle neovascularization with 
synechiae in left eye (Fig. 1). Indirect ophthalmoscopy re-SJ Lee, et al. INTRAVITREAL BEVACIZUMAB OF NEOVASCULAR GLAUCOMA
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Fig. 2. (A) Flouorescein angiography revealed hypofluorescence in the choroid and retinal vessels. (B) An MRI showed occlusion of the left 
carotid artery.
Fig. 3. One day after intravitreal injection of bevacizumab, neovascularization of the iris had almost completely resolved.
vealed narrowing and ghost retinal vessels and a pale optic 
disc. Fluorescein angiography revealed hypofluoresceins in 
the choroid and retinal vessels (Fig. 2A). Magnetic resonance 
angiography indicated significant occlusion of the left carotid 
artery (Fig. 2B). We diagnosed the patient with ocular ischemic 
syndrome and treated him with the maximal tolerable medical 
therapy (timolol and brimonidine, oral acetazolamide and 
intravenous mannitol) for 7 days, but his IOP remained high 
(27-38 mmHg). The use of bevacizumab was discussed as an 
alternative after fully explaining its experimental status for 
ocular neovascular disease. The patient opted for intravitreal 
bevacizumab (Avastin) injection and signed a consent form out-
lining the risk factors, possible side effects, and experimental 
status of the medication. We injected 1.25 mg/0.05mL of 
bevacizumab into the vitreous cavity of the patient’s left eye. 
One day after intravitreous injection of bevacizumab, the 
neovascularization of the iris had almost completely resolved 
(Fig. 3), but the anterior synechiae remained. In addition, IOP 
was 33 mmHg and his visual acuity was unchanged. After 2 
days, the patient underwent left carotid artery stent insertion 
for severe left carotid artery stenosis. He experienced onset 
of severe ocular pain and his IOP was 53 mmHg. He was 
treated with intravenous mannitol and oral acetazolamide, 
which resolved the ocular pain and reduced the patient’s IOP 
to 22 mmHg. After 7 days of injection, we started treatment 
with PRP on the left eye. His IOP was unchanged and the 
regression of neovascularization of the iris persisted. At 10 
days, the regression of neovascularization was still present 
and the IOP was unchanged at 33 mmHg. Since there was no 
longer any ocular pain and light perception had returned, no 
additional surgery was planned. After 8 months, the ocular 
pain had not returned.Korean J Ophthalmol Vol.23, No.2, 2009
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Discussion
Ocular ischemic syndrome occurs secondary to severe carotid 
artery obstruction and involves ocular signs and symptoms 
including corneal edema, rubeosis iridis, neovascular glaucoma, 
hypoperfusion retinopathy, and choroidal perfusion distur-
bance. Neovascular glaucoma is a devastating complication 
caused by ischemic retinopathy secondary to carotid artery 
occlusion. VEGF plays a central role in ocular pathologies 
characterized by neovascularization and increased vascular 
permeabillty.
3 The standard treatment includes retinal photo-
coagulation and cyclodestructive or drainage procedures. In 
this case, panretinal photocoagulation (PRP) was completed 
to decrease the constant rate of VEGF secretion and stop the 
neovascular drive. However, in spite of PRP, the IOP remained 
high.
Bevacizumab is a recombination of humanized anti-VEGF 
IgG
1 approved as an antiangiogenic agent for the treatment of 
metastatic colorectal cancer in combination with chemo-
therapy.
4 It  has the effect of reversing neovascularization by 
controlling VEGF. A recent studiy proposed using bevaci-
zumab intravitreally for age-related macular degeneration.
5 
In the present case, 24 hours after treatment we saw a dramatic 
reduction of iris neovascularization, and no relapse was seen 
within a follow-up time of 10 days. IOP was still high (22-33 
mmHg), however, probably due to chronic NVG with synechiae. 
Other case reports suggest that a single injection of bevaci-
zumab was associated with medically controlled for at least 6 
weeks.
6 However, treatment with bevacizumab seems to have a 
fast, potent effect on neovascular pathologic correlates. In 
conclusion, bevacizumab may be a valuable adjunct in treating 
neovascular glaucoma, though further studies are needed to 
outline optimal time, doses, and patient selection.
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